Syndax Pharmaceuticals (SNDX) to Initiate NDA Submission of

Syndax Pharmaceuticals (SNDX) to Initiate NDA Submission of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Under FDA's Real-Time Oncology Review Program

Syndax Pharmaceuticals (SNDX) to Initiate NDA Submission of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Under FDA's Real-Time Oncology Review Program

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Michaela Metzger , Eytanm Stein , , Drug Administration , Program For Drug Development In Leukemia , Syndax Pharmaceuticals Nasdaq , During The Company , Oncology Center , Syndax Pharmaceuticals , New Drug Application , Real Time Oncology Review , Therapy Designation , Chief Executive Officer , Drug Development , Memorial Sloan Kettering Cancer Center , Principal Investigator ,